Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
Amiloride HCI Tablets, USP 5 mg
Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.
CHMP recommends granting a marketing authorization for Santhera's Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON)
Pathogenesis of multiple sclerosis via environmental and genetic dysregulation of N-glycosylation.
Ocrelizumab in multiple sclerosis: risks and benefits.
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis
Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study.
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.
Slowing of brain atrophy and reductions in new multiple sclerosis lesions sustained at three years in patients treated with Genzyme's LemtradaTM
Abnormalities of Motor Imagery and Relationship With Depressive Symptoms in Mildly Disabling Relapsing-Remitting Multiple Sclerosis.
Diagnosis of exclusion: a case report of probable glatiramer acetate-induced eosinophilic myocarditis.
Protective Associations of HDL with Blood Brain Barrier Injury in Multiple Sclerosis Patients.
Effect of High-Dose Intravenous Methyl-prednisolone Treatment on Intraocular Pressure in Multiple Sclerosis Patients with Relapse.
Review of MR elastography applications and recent developments.
Multiple sclerosis remission following antiretroviral therapy in an HIV-infected man.
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Effects of Panax ginseng in Neurodegenerative Diseases.
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis.
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?

Pages